{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000013","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.622248+00:00","generated_at":"2026-06-07T05:05:58.371562+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"GlycoMimetics signs commercial manufacturing deal with Thermo Fisher's Patheon for uproleselan","bullets":["Agreement covers commercial supply of injectable uproleselan if FDA approves the drug.","Initial term through Dec 31, 2026, auto-renews for 3-year periods unless terminated.","Company provides API; Patheon supplies other raw materials, packaging, and QC testing.","Company gave Patheon a forecast of required annual volumes through 2027.","Either party may terminate after initial term with 18 months' notice; termination fees apply."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000013","json":"https://secwatch.observer/filing/0001558370-24-000013.json","markdown":"https://secwatch.observer/filing/0001558370-24-000013.md","text":"https://secwatch.observer/filing/0001558370-24-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024000013/0001558370-24-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024000013/glyc-20240102x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T05:05:58.371562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"036eb6212b6acc8cb6bf10748511a377a187e9ca","claim":"CRESCENT BIOPHARMA, INC. entered into Project Agreement with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific (effective 2024-01-02).","evidence_excerpt":"On January 2, 2024, GlycoMimetics, Inc. (the “ Company ”) entered into a project agreement (the “ Project Agreement ”) with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific (“ Patheon ”), pursuant to which Patheon will manufacture and supply the Company with its drug candidate, uproleselan, for commercial sale should the Company receive marketing approval from the U.S. Food and Drug Administration.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024000013/0001558370-24-000013-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific"},{"label":"Effective","value":"2024-01-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}